Identification and validation of a prognostic signature based on six immune-related genes for colorectal cancer

• Published in: Discover. Oncology Vol. 15; no. 1; p. 192
• Main Authors: Zheng, Lifeng, Xu, Ziyu, Zhang, Wulou, Lin, Hao, Zhang, Yepeng, Zhou, Shu, Liu, Zonghang, Gu, Xi
• Format: Journal Article
• Language: English
• Published: New York Springer US 28.05.2024; Springer Nature B.V; Springer
• Subjects: Cancer Research; Cancer therapies; Cell death; Colorectal cancer; Gene expression; Immune genes; Immunotherapy; Internal Medicine; Medical prognosis; Medicine; Medicine & Public Health; Molecular Medicine; Nomograms; Oncology; Prognosis; Radiotherapy; Regression analysis; Risk signature; Software; Surgical Oncology; Survival analysis; United States > US; China; Risk signature; Immune genes; Prognosis; Colorectal cancer
• ISSN: 2730-6011; 2730-6011
• DOI: 10.1007/s12672-024-01058-1

Background Colorectal cancer (CRC) is a prevalent malignancy with high mortality and morbidity rates. Although the significant efficacy of immunotherapy is well established, it is only beneficial for a limited number of individuals with CRC. Methods Differentially expressed immune-related genes (DE-IRGs) were retrieved from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and ImmPort databases. A prognostic signature comprising DE-IRGs was developed using univariate, LASSO, and multivariate Cox regression analyses. A nomogram integrating the independent prognostic factors was also developed. CIBERSORT was used to assess immune cell infiltration (ICI). Furthermore, wound-healing, colony formation, migration, and invasion assays were performed to study the involvement of ACTG1 in CRC. Results A signature including six DE-IRGs was developed. The overall survival (OS) rate was accurately estimated for TCGA and GSE38832 cohorts. The risk score (RS) of the signature was an independent factor for OS. Moreover, a nomogram encompassing age, RS, and pathological T stage accurately predicted the long-term OS probability of individuals with CRC. The high-risk group had an elevated proportion of patients treated with ICIs, including native B cells, relative to the low-risk group. Additionally, ACTG1 expression was upregulated, which supported the proliferation, migration, and invasion abilities of CRC cells. Conclusions An immune-related prognostic signature was developed for predicting OS and for determining the immune status of individuals with CRC. The present study provides new insights into accurate immunotherapy for individuals with CRC. Moreover, ACTG1 may serve as a new immune biomarker.